TY  - CONF

T1  - Cost-Effectiveness Analysis of Rivaroxaban in Secondary Prevention of ACS in Sweden

JO  - Value in Health

PY  - 2013/11/01

AU  - Begum N

AU  - Van Hout B

AU  - Thurston S

AU  - Schoeman O

AU  - Fraschke A

AU  - Verheugt FWA

ED  - 

DO  - DOI: 10.1016/j.jval.2013.08.1272

PB  - Elsevier BV

VL  - 16

IS  - 7

SP  - A524

EP  - A524

Y2  - 2024/12/22

ER  -